<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197379</url>
  </required_header>
  <id_info>
    <org_study_id>16-61</org_study_id>
    <nct_id>NCT00197379</nct_id>
  </id_info>
  <brief_title>The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia</brief_title>
  <official_title>The Study for New Effect of Roxithromycin on Androgenetic Alopecia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamamatsu University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is exploiting the new drugs for androgenetic alopecia because there
      are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one
      of the macrolide antibiotics that has immunomodulatory effects. We firstly found that
      roxithromycin increases the rate of murine and human hair follicle elongation in vitro.
      Therefore, we apply this drug on this disease therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The topical therapy for androgenetic alopecia is still not enough to improve cosmetically.
      Thereforem we try to find new effective and safe topical therapy for this disease.
      Roxithromycin has not only antibacterial action but also immunomodulatory and
      anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and
      production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human
      and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply
      roxithromycin on the therapy for androgenetic alopecia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">January 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>Pathological study taken from lesional scalp skin.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alopecia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roxithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Androgenetic alopecia

        Exclusion Criteria:

          -  Cicatricial alopecia

          -  Allergy to roxitromycin

          -  Children (19years old or younger)

          -  Pregnant female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahiro Takigawa, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hamamatsu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.hama-med.ac.jp/</url>
    <description>Hamamatsu University School of Medicine</description>
  </link>
  <reference>
    <citation>Ohshima A, Tokura Y, Wakita H, Furukawa F, Takigawa M. Roxithromycin down-modulates antigen-presenting and interleukin-1 beta-producing abilities of murine Langerhans cells. J Dermatol Sci. 1998 Jul;17(3):214-22.</citation>
    <PMID>9697050</PMID>
  </reference>
  <reference>
    <citation>Ito T, Ito N, Saathoff M, Bettermann A, Takigawa M, Paus R. Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles. Br J Dermatol. 2005 Apr;152(4):623-31.</citation>
    <PMID>15840090</PMID>
  </reference>
  <reference>
    <citation>Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, Paus R. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol. 1997 Dec;151(6):1601-17.</citation>
    <PMID>9403711</PMID>
  </reference>
  <verification_date>April 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>July 28, 2010</last_update_submitted>
  <last_update_submitted_qc>July 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <keyword>androgenetic alopecia</keyword>
  <keyword>roxitromycin</keyword>
  <keyword>apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Roxithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

